Clinical follow-up data of 17 patients with primary cutaneous CD30+ LPD and 1 patient with MF
No. . | Sex . | Age (y) . | Diagnosis . | Site of relapse (mo after diagnosis) . | Current status . | Duration of follow-up (mo) . | p63 expression . | TP63 FISH . |
---|---|---|---|---|---|---|---|---|
1 | M | 63 | C-ALCL | S, LN (29), muscle (29) | DOL | 31 | −* | Normal |
2 | M | 59 | C-ALCL | S, LN (6) | DOL | 19 | − | Normal |
3 | M | 45 | C-ALCL | S, LN (18), lung (18), blood (19) | DOL | 20 | ++† | Normal |
4 | F | 37 | C-ALCL | S, LN (161), bone (167), lung (167), muscle (167) | DOL | 171 | +‡ | Abnormal (43% polyploidy) |
5 | F | 62 | C-ALCL | S, LN (28), lung (32) | DOL | 36 | ++ | Normal |
6 | M | 88 | C-ALCL | S | DOL | 10 | − | Normal |
7 | M | 47 | C-ALCL | LN (4) | DOL | 5 | ±§ | Normal |
8 | F | 67 | C-ALCL | S, LN (12) | DUD | 34 | + | Abnormal (12% polyploidy) |
9 | F | 71 | C-ALCL | — | DUD | 13 | − | Normal |
10 | M | 78 | C-ALCL | — | DUD | 34 | ± | Normal |
11 | M | 54 | C-ALCL | S | AWD | 170 | + | Abnormal (6% polyploidy) |
12 | F | 63 | C-ALCL | Bone (2) | ACR | 90 | ++ | Normal |
13 | M | 80 | C-ALCL | S | ACR | 80 | ± | Normal |
14 | F | 44 | C-ALCL | S | ACR | 141 | − | Normal |
15 | M | 43 | LyP | S, LN (48) | DOL | 51 | ± | Normal |
16 | M | 71 | LyP | S, LN (48), bone marrow (50) | DOL | 53 | − | Normal |
17 | M | 62 | LyP | S | DUD | 158 | − | Normal |
PC | M | 80 | MF | S | DUD | 87 | + | Abnormal (unbalanced translocation with gain of green signal) |
No. . | Sex . | Age (y) . | Diagnosis . | Site of relapse (mo after diagnosis) . | Current status . | Duration of follow-up (mo) . | p63 expression . | TP63 FISH . |
---|---|---|---|---|---|---|---|---|
1 | M | 63 | C-ALCL | S, LN (29), muscle (29) | DOL | 31 | −* | Normal |
2 | M | 59 | C-ALCL | S, LN (6) | DOL | 19 | − | Normal |
3 | M | 45 | C-ALCL | S, LN (18), lung (18), blood (19) | DOL | 20 | ++† | Normal |
4 | F | 37 | C-ALCL | S, LN (161), bone (167), lung (167), muscle (167) | DOL | 171 | +‡ | Abnormal (43% polyploidy) |
5 | F | 62 | C-ALCL | S, LN (28), lung (32) | DOL | 36 | ++ | Normal |
6 | M | 88 | C-ALCL | S | DOL | 10 | − | Normal |
7 | M | 47 | C-ALCL | LN (4) | DOL | 5 | ±§ | Normal |
8 | F | 67 | C-ALCL | S, LN (12) | DUD | 34 | + | Abnormal (12% polyploidy) |
9 | F | 71 | C-ALCL | — | DUD | 13 | − | Normal |
10 | M | 78 | C-ALCL | — | DUD | 34 | ± | Normal |
11 | M | 54 | C-ALCL | S | AWD | 170 | + | Abnormal (6% polyploidy) |
12 | F | 63 | C-ALCL | Bone (2) | ACR | 90 | ++ | Normal |
13 | M | 80 | C-ALCL | S | ACR | 80 | ± | Normal |
14 | F | 44 | C-ALCL | S | ACR | 141 | − | Normal |
15 | M | 43 | LyP | S, LN (48) | DOL | 51 | ± | Normal |
16 | M | 71 | LyP | S, LN (48), bone marrow (50) | DOL | 53 | − | Normal |
17 | M | 62 | LyP | S | DUD | 158 | − | Normal |
PC | M | 80 | MF | S | DUD | 87 | + | Abnormal (unbalanced translocation with gain of green signal) |
ACR, alive and in complete remission; AWL, alive with disease; DOL, died of lymphoma; DUD, died of unrelated disease; F, female; M, male; LN, lymph node; PC, positive control; S, skin.
Tumor cells completely negative.
>75% of tumor cells positive.
30% to 75% of tumor cells positive.
<30% of tumor cells positive.